黄金城游戏

IDT joins forces with Foundation Medicine in AMP workshop

CORALVILLE, IA – 06 November 2014 – At this year’s Association of Molecular Pathology (AMP) meeting, Integrated DNA Technologies (IDT) and Foundation Medicine will explore how nucleic acid innovations are advancing NGS-based diagnostics to improve cancer care. Their joint Corporate Workshop (November 12, 11 am, Maryland Ballroom D) will demonstrate the application of IDT’s target enrichment products and expertise in Foundation Medicine’s cutting-edge, high performance NGS-based assays for accurate and comprehensive cancer genomic profiling. These assays identify targeted treatment options for patients with solid tumors and hematologic malignancies.

Applications that enable clinical research form a major part of IDT’s focus. IDT’s xGen® Lockdown® Probes and Panels enhance target enrichment and allow flexibility in NGS-based assay optimization, while achieving excellent uniformity with virtually no GC bias. The range of custom capture probe panels for targeted NGS can be tailored to cover a wide range of diseases. Dr John Havens, Vice President, Business Development at IDT, will demonstrate IDT’s role in advancing human health during his talk, entitled, “IDT Nucleic Acid Products for Clinical Research and Diagnostics”. Attendees will discover new opportunities for their research and learn how these innovations have been applied in cancer research.

Dr Geoff Otto, Director of Molecular 黄金城游戏 and Sequencing at Foundation Medicine

Foundation Medicine is leading a transformation in cancer care, where each patient’s treatment is informed by a deep understanding of the molecular changes that contribute to their disease. The company has applied NGS to develop and validate robust, sensitive comprehensive genomic profiles that detect all classes of genomic alterations in routine clinical FFPE samples, peripheral whole blood, and bone marrow aspirate. In his talk, entitled, “Building an NGS-Based Platform for Clinical Cancer Care”, Dr Geoff Otto, Director of Molecular 黄金城游戏 and Sequencing at Foundation Medicine, will discuss Foundation Medicine’s comprehensive genomic profiles. These CLIA-certified, CAP-accredited, and NYSDOH-approved tests rely on solution hybrid capture of the coding regions and select intronic regions of hundreds of cancer-related genes. Dr Otto will demonstrate how comprehensive genomic profiling guides selection of targeted therapies and present the successful application of Foundation Medicine’s tests to more than 15,000 patient samples.

The AMP 2014 Annual Meeting (November 12–15, National Harbor, MD, USA) comprises a broad program that encourages inspiring dialogue and discussion among attendees. The theme for this meeting is "Realizing the Dream of Precision Medicine". The collaboration between IDT and Foundation Medicine embraces this goal, delivering NGS technologies that have real-world benefits in the clinic.

For more information, please visit www.idtdna.com .  Follow us on twitter @idtdna for real-time updates and insights.

About IDT
Integrated DNA Technologies (IDT) is the largest supplier of custom nucleic acids in the world, serving academic, government, and commercial researchers in biotechnology, clinical diagnostics, and pharmaceutical development. IDT's primary business is the manufacture of custom, synthetic DNA and RNA oligonucleotides. IDT synthesizes and ships an average of 44,000 custom oligos per day to more than 82,000 customers worldwide. IDT manufacturing locations include facilities in Coralville, Iowa; San Diego, California; Leuven, Belgium; and Singapore. For more information, visit www.idtdna.com .

Integrated DNA Technologies
800-328-2661 (US & Canada)
+1 319-626-8400 (outside US)
[email protected]
www.idtdna.com